A major factor behind the extraordinary success of the fund is the collaboration between the portfolio managers and the medical experts in our Scientific Advisory Board.
THE SCIENTIFIC ADVISORY BOARD PROVIDES IN-DEPTH KNOWLEDGE
The Scientific Advisory Board provides the Investment Team with in-depth knowledge of the scientific basics within medicine, clinical trials, usage, products, companies and market trends. This provides an invaluable basis for the Investment Team’s investment decisions.
GLOBAL CONTACT NETWORK
Each of the Board’s members in turn has an extensive network of medical experts in many different fields, both in Sweden and abroad. In all, there are hundreds of prominent researchers and experts at scientific institutions around the world in this network.
THE EXPERTS ARE CONSULTED REGULARLY
The Investment Team and the Scientific Advisory Board have four quarterly meetings every year with in-depth discussions on topics that are chosen by the Investment Team. The work of the Board is led by its chairman, Professor Sten Nilsson. Henrik Rhenman is the presenter of the material. He calls upon the expertise of the members in subjects that are relevant for the portfolio managers. In addition to the regular quarterly meetings the individual board members are continuously consulted by the portfolio managers.
SCIENTIFIC ADVISORY BOARD
The Scientific Advisory Board is a vital tool in our portfolio management. The expert knowledge of the Board, along with their global network of researchers and experts, provides our portfolio managers with an invaluable platform for their investment decisions.
PROFESSOR STEN NILSSON
CHAIRMAN / PROFESSOR OF ONCOLOGY
Professor of Oncology and affiliated to the Karolinska Institute. Specialist in Oncology and Nuclear Medicine. Former chairman of the Swedish Society of Oncology (SOF), the Swedish Society for Nuclear Medicine (SFNM) and the Swedish Society of Urological Oncology (SFUO). Sten Nilsson has published more than 200 original papers in the scientific literature.
PROFESSOR BERTIL HÅLLSTEN
HONORARY CHAIRMAN / PROFESSOR
Ph.D. in Economics at the Stockholm School of Economics. Professor at the Royal College of Forestry. Has held various positions in asset management at SEB, founder and portfolio manager for SEB Pharmaceutical Fund 1988-1992. Former director at Conpharm, Karo Bio, Meda and Skandigen.
PROFESSOR TOMAS OLSSON
PROFESSOR OF NEUROLOGY
Professor of Neurology, Karolinska Institute. Expert in autoimmune diseases and diseases of the nervous system. Leads neuroimmunological research at the Centre for Molecular Medicine at Karolinska Hospital. Head of the International Society of Neuroimmunology.
PROFESSOR PETER ARNER
PROFESSOR OF MEDICINE
Professor of Medicine, Karolinska Institute. Expert in metabolism, endocrinology and internal medicine. Leads the Lipid laboratory at Karolinska Institute conducting research into diseases in metabolism. Peter Arner has published over 400 scientific papers in international journals and is one of the world’s most cited researchers in obesity-related diseases. Peter has received numerous esteemed scientific awards, including Fernström’s Nordic Prize in Medicine.
DOCTOR OF MEDICINE
Chief surgeon at the Surgical Clinic in Lund, Sweden and is a doctor of medical sciences at the Karolinska Institute (2012). Board member of the scientific group ANDRE, which is part of SADE (the Scandinavian Association for Digestive Endoscopy) and board member of the Endoscopy Committee within the Swedish Association of Gastroenterology. Worked for 14 years at the Karolinska University Hospital Huddinge, as a clinically active surgeon, teacher, lecturer and course provider in surgery and endoscopy. Clinical profile area is minimal-invasive surgery using endoscopic techniques. Has published 20 articles in international scientific journals.
PROFESSOR OF NEUROTRANSMISSION
Previous professor of neurotransmission at farmakologiska institutionen, Karolinska institutet and honorary doctor at pharm faculty, Uppsala university with more than 500 publications of scientific original articles.Recipient of Fernström and Jahre prices.Previous global head of research for AstraZeneca and global research and development president for Eli Lilly. Been part of bringing 25 new medicines to regulatory approval and patients. Cofounder of Aerocrine AB and current board member of Ardelyx, Metabolon,TB Alliance, IAG,Anocca and Betagenon.